1227935-26-3

Basic information

• Product Name: methyl 3-((1-(5-aminopyridin-2-yl)piperidin-4-yloxy)methyl)benzoate
• Synonyms: methyl 3-((1-(5-aminopyridin-2-yl)piperidin-4-yloxy)methyl)benzoate
• CAS NO: 1227935-26-3
• Molecular Weight: 341.41
• Mol File: 1227935-26-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 3-((1-(5-aminopyridin-2-yl)piperidin-4-yloxy)methyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-((1-(5-aminopyridin-2-yl)piperidin-4-yloxy)methyl)benzoate(1227935-26-3)
• EPA Substance Registry System: methyl 3-((1-(5-aminopyridin-2-yl)piperidin-4-yloxy)methyl)benzoate(1227935-26-3)

Safety Data

• Hazardous Substances Data: 1227935-26-3(Hazardous Substances Data)

Upstream product

• 5382-17-2 piperidin-4-ol hydrochloride 
• 1227935-25-2 methyl 3-((1-(5-nitropyridin-2-yl)piperidin-4-yloxy)methyl)benzoate 
• 353258-16-9 1-(5-nitropyridin-2-yl)piperidin-4-ol 
• 1227862-82-9 ethyl 7-(5-aminopyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-3-carboxylate 
• 1227862-80-7 ethyl 7-(5-nitropyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-3-carboxylate 
• 4548-45-2 2-chloro-5-nitropyridine 

Downstream Products

• 1275991-44-0 methyl 3-((1-(5-(3-methyl-5-phenylbenzofuran-2-carboxamido)pyridin-2-yl)piperidin-4-yloxy)methyl)benzoate 

Relevant articles and documents

Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors

The structure-activity relationship studies of a novel series of carboxylic acid derivatives of pyridine-carboxamides as DGAT-1 inhibitors is described. The optimization of the initial lead compound 6 based on in vitro and in vivo activity led to the disc

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).